Orexigen Sets IPO Pricing Range

San Diego-based Orexigen Therapeutics, a biopharmaceutical firm developing treatments for central nervous system disorders, has set the pricing range for the company's IPO. The firm said in a filing with the SEC last night that it will offer 6,000,000 shares of its common stock between $11.00 and $13.00 per share. The company is looking to trade as OREX on the Nasdaq Global Market. The IPO is being underwritten by Merrill Lynch & Co., JPMorgan, JMP Securities, and Leerink Swann & Company. The firm is venture backed by Domain Associates, Kleiner Perkins Caufield and Byers, Montreux Equity Partners, Morgenthaler Ventures, MPM Capital, Scale Venture Partners, Sofinnova Ventures, and Wasatch Advisors.